GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Mechanisms of Variant ER-alpha Function in Breast Cancer

$485,788
Elaine T Alarid · University Of Wisconsin-Madison · R01 · FY2021 · CA

PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma

$485,760
Yi Lin · Mayo Clinic Rochester · R01 · FY2022 · CA

Evaluation of Immune-based Combinations in Prostate Cancer

$485,739
Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Molecular imaging and system dynamics of tumor virotherapy

$485,734
David J Dingli · Mayo Clinic Rochester · R01 · FY2015 · CA

Intracellular Trafficking and Signaling Of The B-cell Antigen Receptor

$485,710
Susan Pierce · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI

Disease Progression Modeling of Bladder Cancer

$485,702
Steve Goodison · Mayo Clinic Jacksonville · R01 · FY2023 · CA

Targeting cysteine import to induce ferroptotic cell death in pancreatic cancer

$485,683
Kenneth P Olive · Columbia University Health Sciences · R01 · FY2024 · CA

Targeting Hypoxia-Induced Cancer-Cell Adaptation by Direct Inhibition of Akt and

$485,596
Maurizio Pellecchia · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2011 · CA

Innate Immune Mechanisms Contributing to Cancer Growth in Obesity

$485,465
Edgar G. Engleman · Stanford University · R01 · FY2022 · CA

Innate Immune Mechanisms Contributing to Cancer Growth in Obesity

$485,465
Edgar G. Engleman · Stanford University · R01 · FY2023 · CA

Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer

$485,357
Deborah W Knapp · Purdue University · U01 · FY2024 · CA

Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling

$485,191
Gabriel Lopez-Berestein · University Of Tx Md Anderson Can Ctr · U01 · FY2019 · CA

Enhancing the efficacy of androgen signaling inhibitors in prostate cancer

$485,160
Xiaoqi Liu · University Of Kentucky · R01 · FY2022 · CA

Enhancing the efficacy of androgen signaling inhibitors in prostate cancer

$485,160
Xiaoqi Liu · University Of Kentucky · R01 · FY2023 · CA

Proj. 2: Combining immune checkpoint blockade with T cell activation

$485,132
E. Antonio Chiocca · Brigham And Women'S Hospital · P01 · FY2021 · CA

ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway

$485,090
Wafik S El-Deiry · Brown University · R01 · FY2020 · CA

Developmental studies to inform clinical stratification and targeting of SHH MB

$484,999
Alexandra L. Joyner · Sloan-Kettering Inst Can Research · R01 · FY2016 · CA

Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes

$484,976
Robert L Ferris · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · CA

Metabolic Control of Immune Suppression in Gliomas

$484,938
Maciej S Lesniak · Northwestern University At Chicago · R01 · FY2017 · NS

Tumor heterogeneity and early outcome prediction: efficacy, timing of MRI and PET

$484,925
Nina A. Mayr · University Of Washington · R01 · FY2014 · CA

NRG Oncology NCORP Research Base-BIQSFP

$484,899
Deborah W Bruner · Nrg Oncology Foundation, Inc. · UG1 · FY2025 · CA

Investigating the Genesis of Tumor Immune Microenvironment (TIME) as a function of Inflammation

$484,830
Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2024 · CA

Prostate Section

$484,825
Peter Pinto · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

Proton-coupled folate/antifolate transport

$484,821
Israel David Goldman · Albert Einstein College Of Medicine, Inc · R01 · FY2016 · CA

Mechanisms of Variant ER-alpha Function in Breast Cancer

$484,754
Elaine T Alarid · University Of Wisconsin-Madison · R01 · FY2023 · CA